表 2.
不同EGFR突变的患者接受免疫联合治疗的近期疗效
Short-term efficacy of combined immunotherapy in patients with different EGFR mutations
| Response | 19del | L858R | Combined with T790M | Other mutation |
| CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate. | ||||
| CR | 0 | 0 | 0 | 0 |
| PR | 4 | 5 | 1 | 1 |
| SD | 2 | 2 | 4 | 3 |
| PD | 0 | 1 | 3 | 1 |
| Total | 6 | 8 | 8 | 5 |
| ORR | 66.67% | 62.50% | 12.50% | 20.00% |
| DCR | 100.00% | 87.50% | 62.50% | 80.00% |